Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.
Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.
All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.
REGENXBIO Inc. (Nasdaq: RGNX) has inaugurated its new Manufacturing Innovation Center in Montgomery County, Maryland, investing $65 million to enhance gene therapy manufacturing capabilities. This facility will produce NAV Technology-based AAV gene therapies at a scale of up to 2,000 liters. It aims to streamline the transition from research to clinical and commercial readiness, supporting REGENXBIO's goal to develop five AAV therapeutics by 2025. The center is designed to meet global regulatory standards and features advanced production and quality control facilities.
REGENXBIO Inc. (Nasdaq: RGNX) appointed Jennifer Zachary to its Board of Directors effective June 3, 2022. With over 20 years of experience in the pharmaceutical and medical device industries, she will also serve on the Audit Committee. Zachary, currently the Executive Vice President and General Counsel of Merck, brings significant legal and regulatory expertise. Her addition is seen as pivotal for REGENXBIO as it implements its '5x'25' strategy aimed at advancing five AAV Therapeutics to pivotal or commercial stages by 2025.
REGENXBIO (RGNX) reports Q1 2022 financial results, highlighting a revenue increase to $22.2 million, primarily from Zolgensma royalties. The company has $765 million in cash, providing operational runway into 2025. Key developments include ongoing enrollment in pivotal trials for RGX-314 targeting wet AMD and diabetic retinopathy, and delayed initiation of the AFFINITY DUCHENNE trial. The in-house cGMP facility is now operational, enhancing manufacturing capacity. CEO Kenneth T. Mills expresses optimism about advancing five AAV Therapeutics into pivotal stages by 2025.
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming investor conferences. The Bank of America Securities 2022 Healthcare Conference will take place on May 10, 2022, at the Encore Hotel in Las Vegas, with a presentation scheduled for 4:00 p.m. PT. The UBS Global Healthcare Conference 2022 is set for May 24, 2022, at Lotte New York Palace, with a presentation at 10:45 a.m. ET. Webcasts of both events will be available on the REGENXBIO website for approximately 30 days following their presentations.
REGENXBIO Inc. (Nasdaq: RGNX) will present at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting from May 16-19, 2022, in Washington, D.C. Key presentations include interim analyses of the RGX-121 and RGX-111 gene therapies for MPS II and MPS I, respectively, and insights on novel AAV vectors. Notable speakers include Nina Hunter, Ph.D., and Roberto Giugliani, M.D., among others. The event highlights REGENXBIO's capabilities in gene therapy, emphasizing its NAV Technology Platform with over 100 AAV vectors developed for various therapeutic areas.
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 4, 2022, at 4:30 p.m. ET to discuss its financial results for Q1 2022 and operational highlights. Interested parties can access the call via phone or a live webcast on the company's website. REGENXBIO focuses on gene therapy, utilizing its proprietary NAV Technology Platform, which includes rights to over 100 novel AAV vectors applicable across various therapeutic areas.
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in a fireside chat at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, scheduled for April 26, 2022, at 8:30 a.m. ET. The virtual conference will allow investors to access a webcast of the chat through REGENXBIO's website, with an archived version available for approximately 30 days afterward. The company focuses on gene therapy, leveraging its proprietary NAV Technology Platform, which includes over 100 novel AAV vectors, to develop treatments across various therapeutic areas.
REGENXBIO Inc. (RGNX) will participate in two investor conferences: the Barclays Global Healthcare Conference on March 17, 2022, at 11:15 a.m. ET in Miami, FL, and the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, in Boston, MA. A live webcast of the Barclays presentation will be available on the company's website, with an archived replay accessible for 30 days. REGENXBIO is a clinical-stage biotechnology firm focused on gene therapy, utilizing its NAV Technology Platform for a variety of therapeutic developments.
REGENXBIO announced a closed eye care collaboration agreement with AbbVie, receiving an upfront payment of $370 million and up to $1.38 billion in additional milestones. The company is advancing its RGX-314 program for wet AMD and diabetic retinopathy, with two pivotal trials ongoing. Positive six-month data from RGX-314 Phase II trials were presented. Additionally, RGX-202 received FDA clearance and designations, with a Phase I/II clinical trial set to begin in 2022. Financially, the company reported revenues of $398.7 million for Q4 2021 and a net income of $294 million.
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its financial results for Q4 and full-year 2021, along with recent operational highlights. Investors can join via phone or webcast, with the recorded version available for 30 days post-call. The company leverages its proprietary NAV® Technology Platform for gene therapy, holding exclusive rights to over 100 novel AAV vectors applicable in various therapeutic areas.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
